Trial Profile
Clofarabine, Gemcitabine, and Busulfan Followed by Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Antithymocyte globulin; Busulfan; Clofarabine; Filgrastim; Methotrexate; Tacrolimus
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 14 Sep 2018 Status changed to discontinued.
- 30 Apr 2018 Status changed from recruiting to completed.
- 14 Jun 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.